Time course and regional basis of Pb-induced changes in MK-801 binding: Reversal by chronic treatment with the dopamine agonist apomorphine but not the D1 agonist SKF-82958

Journal of Neurochemistry

Volumn 68, Issue 5, 1997, Pages 2012-2023

  Cory Slechta, Deborah A ^a,b   McCoy, Lance ^a   Richfield, Eric K ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

801; Apomorphine; Glutamate; Lead; MK; NMDA; SKF 82958

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; LEAD; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AGING; ARTICLE; AUTORADIOGRAPHY; DRUG RECEPTOR BINDING; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

EID: 0030992176     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.68052012.x     Document Type: Article

References (63)

1. Alkondon M., Costa A. C. S., Radhakrishnan V., Aronstam R. S., and Albuquerque E. X. (1990) Selective blockade of NMDA-activated channel currents may be implicated in learning deficits caused by lead. FEBS Lett. 261, 124-130.
2. Andersen P. H. and Jansen J. A. (1990) Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur. J. Pharmacol. 188, 335-347.
3. Angrist B., Rotrosen J., and Gershon S. (1980) Responses to apomorphine, amphetamine and neuroleptics in schizophrenic patients. Psychopharmacology 67, 31-38.
4. Baldessarini R. J., Kula N. S., Zhong R., and Neumeyer J. L. (1994) Receptor affinities of apomorphine enantiomers in rat brain tissue. Eur. J. Pharmacol. 254, 199-203.
5. Bellinger D., Leviton A., Waternaux C., Needleman H., and Rabinowitz M. (1987) Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N. Engl J. Med. 316, 1037-1043.
6. Bellinger D., Sloman J., Leviton A., Rabinowitz M., Needleman H. L., and Waternaux C. (1991) Low-level lead exposure and children's cognitive function in the preschool years. Pediatrics 87, 219-227.
7. Bresink I., Danysz W., Parsons C. G., Tiedtke P., and Mutschler E. (1995) Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats. J. Neural Transm. Gen. Sect. 10, 11-26.
8. Buller A. L., Larson H. C., Schneider B. E., Beaton J. A., Morrisett R. A., and Monaghan D. T. (1994) The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J. Neurosci. 14, 5471-5484.
9. 2+ reduces voltage- and N-methyl-D-aspartate (NMDA)-activated calcium channel currents. Cell Mol. Neurobiol. 14, 711-722.
10. Cohn J., Cox C., and Cory-Slechta D. A. (1993) The effects of lead exposure on learning in a multiple schedule of repeated acquisition and performance. Neurotoxicology 14, 329-346.
11. Corsini G. U., Del Zompo M., Manconi S., Cianchetti C., Mangoni A., and Gessa G. L. (1977) Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv. Biochem. Pharmacol. 16, 645-649.
12. Cory-Slechta D. A. (1988) Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. J. Pharmacol. Exp. Ther. 246, 840-851.
13. Cory-Slechta D. A. (1995a) MK-801 subsensitivity following post-weaning lead exposure. Neurotoxicology 16, 85-96.
14. Cory-Slechta D. A. (1995b) Relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic and glutamatergic neurotransmitter system functions. Annu. Rev. Pharmacol. Toxicol. 35, 391-415.
15. Cory-Slechta D. A. and Pokora M. J. (1991) Behavioral manifestations of prolonged lead exposure initiated at different stages of the life cycle: I. Schedule-controlled responding. Neurotoxicology 12, 745-760.
16. Cory-Slechta D. A., Weiss B., and Cox C. (1985) Performance and exposure indices of rats exposed to low concentrations of lead. Toxicol Appl. Pharmacol. 78, 291-299.
17. Cory-Slechta D. A., Weiss B., and Cox C. (1987) Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J. Pharmacol. Exp. Ther. 243, 804-813.
18. Cory-Slechta D. A., Garcia-Osuna M., and Greenamyre T. J. (1996a) Lead-induced changes in NMDA receptor complex binding: correlations with learning accuracy and with sensitivity to learning impairments caused by MK-801 and NMDA. (Abstr.) Fundam. Appl. Toxicol. 30, 24.
19. Cory-Slechta D. A., Garcia-Osuna M., and Greenamyre T. J. (1996b) Lead-induced changes in NMDA receptor binding: correlations with learning accuracy and with sensitivity to learning impairments caused by MK-801 and NMDA administration. Behav. Brain Res. (in press).
20. Cory-Slechta D. A., Pokora M. J., Fox R. A. V., and O'Mara D. J. (1996c) Lead-induced changes in dopamine D1 sensitivity: modulation by drug discrimination training. Neurotoxicology 17, 445-458.
21. Cory-Slechta D. A., Pokora M. J., and Johnson J. L. (1996d) Post-weaning lead exposure enhances the stimulus properties of N-methyl-D-aspartate: possible dopaminergic involvement? Neurotoxicology 17, 509-522.
22. Davidson M., Kendler K. S., Davis B. M., Horvath T. B., Mohs R. C., and Davis K. L. (1985) Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients. Psychiatry Res. 16, 95-99.
23. Ferrier I. N., Johnstone E. C., and Crow T. J. (1984) Clinical effects of apomorphine in schizophrenia. Br. J. Psychiatry 144, 341-348.
24. Gao Y., Baldessarini R. J., Kula N. S., and Neumeyer J. L. (1990) Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J. Med. Chem. 33, 1800-1805.
25. Guilarte T. R. and Miceli R. C. (1992) Age-dependent effects of lead on [3H]MK-801 binding in NMDA receptor-gated ionophore: in vitro and in vivo studies. Neurosci. Lett. 148, 27-30.
26. 3H]-MK-801 binding sites in adult rat forebrain. Eur. J. Pharmacol. 248, 273-275.
27. 2+ neurotoxicity. Neurotoxicology 15, 459-467.
28. Ishihara K., Alkondon M., Montes J. G., and Albuquerque E. X. (1995) Ontogenetically related properties of N-methyl-D-aspartate receptors in rat hippocampal neurons and the age-specific sensitivity of developing neurons to lead. J. Pharmacol. Exp. Ther. 273, 1459-1470.
29. Jett D. A. and Guilarte T. R. (1995) Developmental lead exposure alters N-methyl-D-aspartate and muscarinic cholinergic receptors in the rat hippocampus: an autoradiographic study. Neurotoxicology 16, 7-18.
30. 3H]dizocilpine (MK-801) binding in rat brain. Soc. Neurosci. Abstr. 18, 978.
31. Kutsuwada T., Kashiwabuchi N., Mon H., Sakimura K., Kushiya E., Araki H., Meguro H., Masaki T., Kumanishi T., Arakawa M., and Mishina M. (1992) Molecular diversity of the NMDA receptor channel. Nature 358, 36-41.
32. Lasley S. M. (1992) Regulation of dopaminergic activity, but not tyrosine hydroxylase, is diminished after chronic inorganic lead exposure. Neurotoxicology 13, 625-636.
33. Lasley S. M. and Lane J. D. (1988) Diminished regulation of mesolimbic dopaminergic activity in rat after chronic inorganic lead exposure. Toxicol. Appl. Pharmacol. 95, 474-483.
34. Laurie D. J. and Seeburg P. H. (1994) Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268, 335-345.
35. Magnusson K. R. (1996) Glycine enhances binding to the NMDA receptor complex in aged mice but does not correct the aging change. J. Gerontol. A Biol. Sci. Med. Sci. 51, B141-B147.
36. 125I-labeled CGP-55802A. Proc. Natl. Acad. Sci. USA 90, 8434-8438.
37. Maura G., Giardi A., and Raiteri M. (1988) Release-regulating D2 dopamine receptors are located on striatal glutamatergic nerve terminals. J. Pharmacol. Exp. Ther. 247, 680-684.
38. McCoy L. and Richfield E. K. (1996a) Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett. 213, 137-141.
39. McCoy L. and Richfield E. K. (1996b) Washable endogenous substances and regional heterogeneity in agonist enhanced [3H]MK-801 binding in rat brain sections. Brain Res. 710, 103-111.
40. 3H]-glutamic acid release by dopaminergic drugs. Life Sci. 26, 2073-2081.
41. Molinoff P. B., Williams K., Pritchett D. B., and Zhong J. (1994) Molecular pharmacology of NMDA receptors: modulatory role of NR2 subunits. Prog. Brain Res. 100, 39-45.
42. Monyer H., Burnashev N., Laurie D. J., Sakmann B., and Seeburg P. H. (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12, 529-540.
43. Muller W. E., Stoll S., Scheuer K., and Meichelbock A. (1994) The function of the NMDA-receptor during normal brain aging. J. Neural Transm. Suppl. 44, 145-158.
44. Omelchenko I. A., Nelson C. S., Marino J. L., and Allen C. N. (1996) The sensitivity of N-methyl-D-aspartate receptors to lead inhibition is dependent on the receptor subunit composition. J. Pharmacol. Exp. Ther. 278, 15-20.
45. Pokora M. J., Richfield E. K., and Cory-Slechta D. A. (1996) Preferential vulnerability of nucleus accumbens dopamine binding sites to low-level lead exposure: time course of effects and interactions with chronic dopamine agonist treatments. J. Neurochem. 67, 1540-1550.
46. Reynolds G. P. (1995) Neurotransmitter systems in schizophrenia. Int. Rev. Neurobiol. 38, 305-339.
47. Reynolds G. P. and Czudek C. (1995) New approaches to the drug treatment of schizophrenia. Adv. Pharmacol. 32, 461-503.
48. Reynolds I. J. and Miller R. J. (1990) Allosteric modulation of N-methyl-D-aspartate receptors. Adv. Pharmacol. 21, 101-126.
49. Rice D. C. (1985) Chronic low-lead exposure from birth produces deficits in discrimination reversal in monkeys. Toxicol. Appl. Pharmacol. 75, 201-210.
50. Riederer P., Lange K. W., Kornhuber J., and Danielczyk W. (1992) Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung 42, 265-268.
51. Riva M. A., Tascedda F., Molteni R., and Racagni G. (1994) Regulation of NMDA receptor subunit mRNA expression in the rat brain during postnatal development. Mol. Brain Res. 25, 209-216.
52. Scharding N. N. and Oehme F. W. (1973) The use of animal models for comparative studies of lead poisoning. Clin. Toxicol. 6,419-424.
53. Seeman P. and Van Tol H. M. (1994) Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15, 264-270.
54. Skirboll L. R., Grace A. A., and Bunney B. S. (1979) Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science 206, 80-82.
55. Smith R. C., Tamminga C., and Davies J. M. (1977) Effect of apomorphine on schizophrenic symptoms. J. Neural Transm. Gen. Sect. 40, 171-176.
56. Ujihara H. and Albuquerque E. X. (1992) Developmental change of the inhibition by lead of NMDA-activated currents in cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 263, 868-875.
57. 2+ modulates the NMDA-receptor-complex channel. Naunyn Schmiedebergs Arch. Pharmacol. 347, 209-213.
58. Widzowski D. V., Finkelstein J. N., Pokora M. J., Johnson S. C., and Cory-Slechta D. A. (1994) Time course of postnatal lead-induced changes in dopamine receptors and their relationship to changes in dopamine sensitivity. Neurotoxicology 15, 294-308.
59. Winder C., Garten L. L., and Lewis P. D. (1983) The morphological effects of lead on the developing central nervous system. Neuropathol. Appl. Neurobiol. 9, 87-108.
60. 2+ reduces the current from NMDA receptors expressed in Xenopus oocytes. FEBS Lett. 377, 390-392.
61. Yamamoto B. K. and Davy S. (1992) Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58, 1736-1742.
62. Youngren K. D., Daly D. A., and Moghaddam B. (1993) Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther. 264, 289-293.
63. Zhong J., Carrozza D. P., Williams K., Pritchett D. B., and Molinoff P. B. (1995) Expression of mRNAs encoding subunits of the NMDA receptor in the developing rat brain. J. Neurochem. 64, 531-539.